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with chronic left ventricular dysfunction at increased risk for sudden cardiac death as 
compared to current risk stratiﬁcation methods for selection of patients for implanted 
cardiac deﬁbrillators (ICD) versus medical therapy. METHODS: A Markov model 
was developed to evaluate the impact of using AdreView for evaluating NYHA II or 
III heart failure (HF) patients with LV ejection fraction (EF) <50% for treatment with 
an ICD. AdreView risk-stratiﬁcation was used to guide the treatment decision between 
ICD and medical therapy. The source of data for predicted probabilities, expected 
mortality rates, and treatment costs in year 2009 dollars are from the published litera-
ture and the AdreView Myocardial Imaging for Risk Evaluation in Heart Failure 
(ADMIRE-HF) study. The model was developed from a societal perspective using a 
one-month cycle time, 3% discount rate and a lifetime time horizon. Sensitivity analy-
sis was completed on cost, efﬁcacy and relative risk ratios. RESULTS: AdreView had 
an incremental cost-effectiveness ratio (ICER) of $100,910 versus standard stratiﬁca-
tion methods. The number needed to screen to prevent one death over 5 years was 
20. The model was sensitive to changes in utility values ($91,737–$112,123 / QALY), 
efﬁcacy of ICD in low risk patients ($95,805–$107,388 / QALY) and efﬁcacy of ICD 
in high risk patients ($81,578–$166,086 / QALY). The model was not sensitive 
AdreView cost, even at 200% of baseline ($104,068 / QALY). CONCLUSIONS: 
AdreView is a relatively cost-effective screening strategy versus current methods that 
can prevent sudden cardiac deaths within as few as 20 patient screenings. Further 
research on the use of AdreView in real-world settings is warranted.
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COST-EFFECTIVENESS OF ROSUVASTATIN FOR THE PRIMARY 
PREVENTION OF VASCULAR EVENTS ACCORDING TO FRAMINGHAM 
RISK SCORE IN PATIENTS WITH AN ELEVATED C-REACTIVE PROTEIN
MacDonald GP
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OBJECTIVES: Compare the cost-effectiveness of rosuvastatin versus standard man-
agement according to Framingham risk for the primary prevention of vascular events 
in JUPITER-like patients that had LDL levels less than 130 mg/dL and CRP levels of 
2.0 mg/L or higher. METHODS: TreeAge Pro 2009 software was used to design 2 
Markov-type models from a third party payer perspective to calculate the incremental 
cost-effectiveness ratio (ICER) of rosuvastatin 20 mg versus standard management 
over 10 years in patients with a Framingham Risk Score greater than 10% and less 
than or equal to 10%. Cost data were obtained from CMS and the Redbook. Quality 
of life measures were obtained from the literature. Event data were obtained directly 
from the JUPITER Study Group. One-way sensitivity analysis and probabilistic sen-
sitivity analysis were conducted on many possible ranges of cost, quality of life 
measures, and event rates. RESULTS: Treating patients with rosuvastatin to prevent 
vascular events would result in an estimated ICER of $37,232/QALY and $95,000/
QALY in those with Framingham Risk Scores greater than 10%, and less than or 
equal to 10%, respectively. Results of 1-way sensitivity analysis were especially sensi-
tive to the price of the rosuvastatin and the probability of a primary endpoint event 
in the standard management group. Results of a probabilistic sensitivity analysis 
suggest that in patients with a Framingham score greater than 10%, the probability 
that rosuvastatin would be considered cost-effective at a $50,000/QALY threshold is 
approximately 97.5%. In those patients with a Framingham Risk Score less than or 
equal to 10%, the probability that rosuvastatin would be considered cost-effective is 
less than 1%. CONCLUSIONS: Compared with standard management practices, 
statin therapy with rosuvastatin may be a cost-effective strategy over a 10-year time 
horizon for preventing vascular events in patients with a Framingham Risk Score 
greater than 10% that have normal LDL levels and elevated CRP levels.
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CONSIDERING THE COST-EFFECTIVENESS OF STATINS IN FAMILY 
PRACTICE IN TURKEY FROM A PAYER PERSPECTIVE
Koçkaya G
Yeditepe University, Istanbul, Turkey
OBJECTIVES: In Turkey, there is Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin 
and Simvastatin in the statin market. And all statins are reimbursed by health insur-
ance companies.The aim of this study is to determine the cost-effective statins which 
are reimbursted by the Social Security Foundation,the biggest reimburestment founda-
tion in Turkey. METHODS: A cost-effectiveness analysis was designed from the 
perspective of the insurance company view. For insurance company data; Social 
Security Foundation which is the biggest reinburstment foundation in Turkey was 
chosen. The assumed treatment protocol depended on the one in the Republic of 
Turkey Health Ministery Primary Care Diagnosis and Treatment Guide which was 
published in 2003.The values of the mean effectiveness of statins are taken from a 
published meta-analysis. RESULTS: Simvastatin had the lowest cost in the ﬁrst year 
of therapy ($166), followed by pravastatin ($300),ﬂuvastatin ($365),rosuvas-
tatin($437) and atorvastatin($448). When the drugs were compared for the incremen-
tal cost-effectiveness, simvastatin dominated pravastatin and ﬂuvastatin,whereas 
rosuvastatin dominated atorvastatin.The ﬁrst year incremental cost of rosuvastatin 
was $271 compared to simvastatin, or $30 per additional 1% reduction in LDL-C, 
$225 per additional 1% increase in HDL-C and $1856 per additional patients to ATP 
II goal. CONCLUSIONS: Because simvastatin had a lower acquisition cost than all 
statins and its all dosages cost approximately 1/3 of the nearest alternative statin, in 
our base case and alternative scenarios simvastatin was the least costly alternative. 
Thus depending on actual acquisition prices and following costs such as doctor visits 
and laboratories the payer may achieve substantial cost savings and greater effective-
ness by using rosuvastatin or simvastatin instead of these agents in Turkey. Therefore, 
simvastatin and rosuvastatin comprise of the optimal two statin formulary. Formulary 
desicion based on these results should be revisited periodically, as new pricing, out-
comes and safety data become available.
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OBJECTIVES: To evaluate the cost-effectiveness of treating patients without tradi-
tional risk factors for cardiovascular disease with statins. METHODS: Cost-effective-
ness was evaluated using a backward induction model. A hypothetical cohort of men 
and women aged 40 to 80 years was evaluated for their ﬁrst acute myocardial infarction 
(AMI) or cardiovascular accident (CVA). The Reynolds Risk Score (RRS) was used to 
generate event risks and risk reductions as the impact of therapy on lipids and c-reactive 
protein (CRP) could be calculated independently. Covariates for the RRS were adapted 
from the JUPITER trial and national health statistics. Life expectancies, quality of life 
adjustments, and event costs for AMI and CVA were ascertained from the primary 
literature. Direct and indirect treatment costs were based on the primary literature, 
Adult Treatment Panel III (ATPII) protocols and the Bureau of Labor Statistics. Medi-
cation costs were adapted from the Federal Supply Schedule. Costs were inﬂated to 
2009 US$ using the medical component of the CPI and discounted at a rate of 3%. A 
sensitivity analysis was also performed. RESULTS: Using a threshold of $150,000 per 
QALY, treatment was cost-effective with generic statins in all men and women, aged 
40 to 80 years when both CRP and LDL levels were affected. It was cost-effective to 
treat men >60 years with a hypothetical medication that only affected CRP levels. In 
the base case (65 year old men/women), the model was sensitive to adherence, smoking 
status (women), premature family history of AMI, brand rosuvastatin price, and the 
level of LDL reduction. CONCLUSIONS: In this population, it is cost-effective to treat 
all patients for the primary prevention of AMI and CVA with a generic statin that 
confers therapeutic beneﬁts similar to what was modeled in this study. Selectively 
lowering CRP levels is only cost-effective in males >60 years.
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ROBUST UNIVARIATE AND MULTIVARIATE SENSITIVITY ANALYSIS 
CONFIRM THAT ENOXAPARIN IS COST-SAVING TO THE PAYERS 
COMPARED WITH UFH FOR VTE PREVENTION IN PATIENTS WITH 
ISCHEMIC STROKE: ANALYSIS OF THE PREVAIL DATA
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OBJECTIVES: A decision-analytic model using cost data and clinical information 
from the PREVAIL study showed that enoxaparin was cost-saving from the payer 
perspective compared with unfractionated heparin (UFH) for the prevention of venous 
thromboembolism (VTE) in patients with acute ischemic stroke (overall costs of clini-
cal events plus drug costs: $2018 vs. $2913, respectively; difference $895 per patient). 
To test the robustness of the cost difference of enoxaparin versus UFH for VTE 
prevention after an acute ischemic stroke, univariate and multivariate sensitivity 
analyses were performed. METHODS: In the univariate analysis, the payer cost 
(2007$) for each clinical event (deep-vein thrombosis [DVT], pulmonary embolism 
[PE]; intracranial hemorrhage [ICH], major extracranial hemorrhage [MjEH] and 
minor extracranial hemorrhage [MnEH]) was adjusted individually, increasing or 
decreasing by 20%, while other parameters (drug costs, event rates) remained 
unchanged. The multivariate analysis was a Monte Carlo simulation (Crystal Ball 
software), where all the parameters were simultaneously varied in a random fashion 
within a range of ± 20% over 10,000 trials. RESULTS: The cost of DVT was $13,499. 
When increased by 20% to $16,199, the difference between UFH and enoxaparin 
groups was $1,104; when decreased by 20% to $10,799, the difference was $686. 
The baseline costs were $20,635 for PE, $26,037 for ICH, $22,765 for MjEH and 
$815 for MnEH. When these were increased by 20%, the difference between enoxa-
parin and UFH groups was $928, $907, $859 and $896, respectively. When decreased 
by 20%, the difference was $862, $883, $932 and $894. Using the Monte Carlo 
simulation multivariate analysis, the difference varied between $615 and $1,177, with 
mean (SD) $896 ($91) and median of $897. Enoxaparin was less costly than UFH 
across all analyses, with DVT being the main cost driver. CONCLUSIONS: Univariate 
and multivariate sensitivity analysis conﬁrmed that enoxaparin is more cost-saving 
than UFH for VTE prevention after an acute ischemic stroke.
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OBJECTIVES: To identify, retrieve, and summarize studies evaluating the cost-effec-
tiveness of selected cardiac imaging tests for the diagnosis of CAD. METHODS: 
A164 Abstracts
Medline and the National Health Service Economic Evaluation Database (NHSEED) 
were searched from their inception up to October 2009. Included studies were those 
full economic evaluations describing both costs and consequences of a) CT angiogra-
phy; b) MRI; c) SPECT; and d) stress ECHO in the diagnosis of CAD. Article selection 
was performed by independent pairs of researchers. Target data for extraction 
included: study ﬁrst author and year of publication, imaging tests compared, type of 
economic analysis, reported costs and outcomes, incremental cost-effectiveness ratio 
(ICER), currency, and patient characteristics (i.e., known or suspected CAD and risk 
of CAD). The primary outcome of interest for the present systematic review was the 
ICER of each imaging test in relation to another test of interest being compared. 
RESULTS: A total of 12 studies were identiﬁed. Overall, of the selected strategies, 
stress ECHO was the most compared, followed by SPECT, and CT angiography and 
MRI. Results showed that (despite fewer studies) CT angiography was considered 
cost-effective in all comparisons, however in speciﬁc situations such as in the presence 
of high likelihood or prevalence of CAD or versus stress ECHO and MRI (no com-
parison was found against SPECT). Under base-case (average) situations, stress ECHO 
was reported to be relatively cost-effective, especially in contrast with SPECT and 
MRI, but not CT angiography. SPECT follows with few positive cost-effectiveness 
results, and MRI did not achieve any cost-effectiveness over the other remaining 
strategies. CONCLUSIONS: Therefore, according to the published economic data 
from the literature, a cost-effectiveness ranking is proposed for the four analyzed 
cardiac imaging strategies as follows: CT angiography (in the presence of high likeli-
hood or prevalence of CAD) > stress ECHO > SPECT > MRI.
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COST EFFECTIVENESS ANALYSIS THE PREVENTION OF VENOUS 
THROMBOEMBOLISM IN IMMOBILIZED PATIENTS (PREVENT) TRIAL: 
THROMBOPROPHYLACTIC TREATMENT WITH DALTEPARIN VERSUS 
PLACEBO IN ACUTELY ILL PATIENTS
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OBJECTIVES: Use of venous thromboembolism (VTE) prophylaxis among hospital-
ized patients is very low at approximately 42% (Goldhaber 2004). This analysis 
quantiﬁes whether thromboprophylactic treatment with dalteparin in acutely ill 
patients is cost saving due to avoided VTE. METHODS: Randomized clinical trial 
VTE data from the Prevention of Venous Thromboembolism in Immobilized Patients 
(PREVENT) trial were used to determine dalteparin and placebo VTE event rates. 
Costs were obtained from two published sources Oster et al. (2004) and MacDougall 
et al. (2006). Oster et al. reports on short term charged costs (90 days) while Mac-
Dougall et al. on long term (one year) paid costs. Costs were converted to 2008 US 
dollars using the CPI. Cost for dalteparin was calculated as $29.34 (2009 WAC 
pricing) for 5000 IU once daily for 14 days, while the cost of placebo is zero. 
RESULTS: In PREVENT, 2991 patients were randomized (1518 to dalteparin, 1473 
to placebo). Dalteparin patients experienced 32 VTE events while placebo had 64. 
The short term cost of in-hospital VTE was $17,552 higher than matched controls (P 
< 0.01) and short term post-discharge VTE cost was $5765 higher than matched 
controls (P = 0.01) (Oster et al.), while the long term annual adjusted mean total 
claims cost was $30,400 (MacDougall et al.). In aggregate, VTE events cost $1,393,914 
for dalteparin patients versus $1,550,112 for placebo in the short term with a cost 
savings of $156,197 for patients utilizing dalteparin. The total annual costs for treat-
ing 32 VTE patients plus cost of dalteparin was $1,783,425 as compared to $2,329,132 
for treating 64 VTE patients on placebo, giving an annual cost savings of $545,708 
for utilizing dalteparin. CONCLUSIONS: Thromboprophylactic treatment with dalte-
parin reduces short term costs by $156,197 ($102.89 per person) and long term annual 
costs by $545,708 ($359.49 per person) in acutely ill patients at risk for VTE.
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A PHARMACOECONOMICS ASSESSMENT OF SILDENAFIL IN THE 
MANAGEMENT OF PULMONARY ARTERIAL HYPERTENSION IN 
PEDIATRICS: THE MEXICAN CASE
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic disabling condition 
that affects both adults and children. The aim of this study was to evaluate the cost-
effectiveness of sildenaﬁl to manage PAH in pediatric (<18 years), functional class III, 
patients, who have failed previously to calcioantagonists, from the Mexican institu-
tional perspective. METHODS: A ﬁve-state Markov model was performed to estimate 
one year costs and health consequences (one-month cycle). Effectiveness measures 
were: increase in cardiac index (%) and exercise tolerance (%), as well as reduction 
in pulmonary vascular resistance (%), hospital length of stay (LOS, days) and discon-
tinuation rate due to adverse events. Transition probabilities were obtained from a 
meta-analysis involving national and international published literature. Doses of com-
parators used in the assessment were sildenaﬁl (60 mg/day) and bosentan (125 mg/
day, reference alternative). Resource use and costs were obtained from hospital records 
(n = 120) from the Instituto Mexicano del Seguro Social. Costs include hospital stay, 
laboratory and respiratory function tests, imagenology, drugs and adverse events 
management. The model was validated according to international guidelines. Sensitiv-
ity analyses were performed employing bootstrapping techniques. RESULTS: Per 
patient associated costs for sildenaﬁl, and bosentan were [CI 95%]: US$13,373 
[US$11,965–US$15,495] and US$20,110 [US$19,589–US$20,631], respectively. 
Sildenaﬁl is associated to an increase of 8.05% [7.87%–8.24%] in cardiac index and 
of 10.14% [9.96%–10.33%] in exercise tolerance, as well as to a reduction of 1.5% 
[1.32%–1.68%] in pulmonary vascular resistance, 11.54 [11.36–11.72] in discontinu-
ation rate (per 1000) and 8.90 days [8.72 days–9.09 days] in LOS, respectively. In 
consequence, sildenaﬁl represents the most attractive therapy to manage PHA in terms 
of cost-effectiveness. CONCLUSIONS: In the Mexican institutional setting, sildenaﬁl 
demonstrated to be a cost-saving therapy to manage PHA in pediatric, functional class 
III, patients,wich should be considered in order to allocate institutional resources 
efﬁciently.
PCV79
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OBJECTIVES: Updated clinical practice guidelines recommend antithrombotic agents 
to minimize complications and deaths following UA/NSTEMI events. The purpose of 
this study was to estimate the cost-effectiveness of different antithrombotic agents in 
the management of UA/NSTEMI, from the institutional perspective. METHODS: A 
seven-state Markov model was performed to estimate health and economic conse-
quences during a time horizon of ﬁve weeks (one–week cycles). Effectiveness measures 
were reduction in incidence of acute myocardial infarct (AMI) and recurrence of 
angina, as well as avoided events of myocardial revascularization and deaths associ-
ated to acute coronary syndrome. Transition probabilities were obtained from a 
meta-analysis employing international published literature. Doses of comparators 
were: dalteparin (240 UI/kg/day); enoxaparin (2 mg/kg/day); fondaparinux(5 mg/
day); nadroparin(172 IU/kg/day) and unfractionated heparin(UFH 15,000 IU/day). 
Resource use was obtained from the Social Security Mexican Institute hospital records 
(n = 5000). Costs were extracted from government and institutional sources and 
include hospitalization, drugs, medical procedures, imagenology, laboratory tests and 
adverse events management. Probabilistic sensitivity analyses were performed employ-
ing bootstrapping techniques. Acceptability curves were constructed. RESULTS: 
Dalteparin, enoxaparin, fondaparinux, nadroparin and UHF (reference alternative) 
associated costs per patient were: US$2501 (+19%), US$2531 (+20%), US$2226 
(+6%), US$2556 (+21%) and US$2179, respectively. Dalteparin is the only alternative 
that exhibits better health outcomes than reference in all considered effectiveness 
measures (p < 0.05 in AMI and myocardial revascularization). Incremental cost-
effectiveness ratios (ICER [CI95%]) for dalteparin compared to UHF were US$10,916 
[US$10,703-US$11,128] and US$3,509 [US$3,440-US$3,577], per additional AMI 
reduced and additional myocardial revascularization avoided, respectively. At a will-
ingness to pay of US$15,800 per additional AMI avoided, acceptability curves showed 
that the probability that dalteparin be cost-effective is close to one, while for enoxa-
parin is negligible. CONCLUSIONS: Regarding AMI reduction and avoided myocar-
dial revascularization, dalteparin represents a cost-effective antithrombotic therapy in 
Mexican patients who suffered UA/NSTEMI due its higher efﬁcacy and reasonable 
incremental costs.
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OBJECTIVES: The purpose was to conduct a cost-effectiveness analysis (CEA) of 
enoxaparin versus fondaparinux in the treatment of deep-vein thrombosis (DVT) in 
Poland. METHODS: Data concerning efﬁcacy and safety of compared therapies were 
taken from the clinical-effectiveness analysis which was based on the systematic litera-
ture review. Due to lack of statistically signiﬁcant differences in comparison of enoxa-
parin versus fondaparinux, economic proﬁtability estimation was performed as a 
cost-minimisation analysis. Decision model was created by using MS Excel. Total costs 
of analysed therapies were estimated from the perspective of both payers in Poland 
(National Health Fund and patient). The minimisation analysis involved comparison 
of treatment with enoxaparin (1 mg/kg body mass, twice daily) versus fondaparinux 
(5; 7,5 or 10 mg—depending on the patient’s body mass, once daily). The time horizon 
of the analysis was 3 months (consistent with clinical trials). It was assumed that 
efﬁciency of interventions in that period of observation was constant. The costs were 
not discounted. The stability of obtained results was checked in one-way and two-way 
sensitivity analysis through change of key parameters and assumptions of the model. 
RESULTS: The results of the cost-minimisation analysis are as following: treatment 
of one patient using enoxaparin in the 3 month time horizon is 312.50 PLN cheaper 
than fondaparinux therapy. Clinical effects of assessed treatment strategies are com-
parable, based on the data from randomised clinical trials. One-way and two-way 
sensitivity analysis proved that therapy with enoxaparin is a less costly than with 
fondaparinux in the treatment of deep-vein thrombosis for most parameters taken into 
account in the sensitivity analysis. CONCLUSIONS: Treatment of deep-vein throm-
bosis using enoxaparin is a less expensive option in comparison with fondaparinux 
from both payers’ perspective (National Health Fund and patient) in Poland.
